Polyserine Fusion Peptides for Selective Tau Aggregate Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective mechanisms to target and modulate tau aggregates, which are toxic to cells and contribute to neurodegenerative diseases like Alzheimer's and frontotemporal dementia, without disrupting the normal function of soluble tau.
Innovation Solution
Employing polyserine repeat sequences to target heterologous peptides to tau aggregates, using fusion peptides with domains like UBXD8/FAF2 to suppress aggregation, and downregulating PNN expression with siRNA to inhibit tau formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If molecular chaperones or disaggregases are used to disassemble tau aggregates, then tau aggregate toxicity is reduced, but the balance may shift to smaller seeding-competent species that drive more misfolding
Solution Approach 1:
The patent extracts and targets specific tau aggregate structures using polyserine repeat sequences that selectively bind to aggregated tau conformations. This approach removes toxic aggregates through selective binding and recruitment of degradation machinery, rather than forcing disassembly that could generate harmful seeding-competent species.
Solution Approach 2:
The patent introduces polyserine repeat-containing fusion proteins as intermediary molecules that bridge tau aggregates and cellular degradation systems. These fusion proteins act as mediators that recruit tau aggregates to degradation pathways without directly disrupting aggregate structure, thereby avoiding the generation of seeding-competent species.
2Productivity
If proteins are targeted to tau aggregates to suppress aggregation, then aggregation is reduced, but normal soluble tau function may be disrupted
Solution Approach 1:
The patent applies local quality by designing polyserine repeat sequences that specifically target aggregated tau conformations while leaving soluble tau unchanged. The polyserine repeats exhibit selective binding affinity for beta-sheet rich aggregated structures, allowing aggregation suppression in affected regions without interfering with normal soluble tau function in healthy compartments.
3Measurement precision
If polyserine repeat sequences are used to target heterologous peptides to tau aggregates, then specific targeting is achieved, but the complexity of fusion peptide design increases
Solution Approach 1:
The patent segments the targeting function into a modular polyserine repeat domain that can be independently designed and combined with various functional domains. This segmentation allows the polyserine targeting module to be separated from the effector domain, simplifying the overall design process while maintaining high targeting specificity.
Solution Approach 2:
The patent creates universal polyserine repeat modules that can be combined with multiple different effector domains (degradation tags, fluorescent labels, etc.). This universality reduces design complexity by providing a standardized targeting platform that works across different therapeutic strategies, eliminating the need to redesign the targeting sequence for each application.
Data Source
AI summary
The present invention includes novel methods and compositions for targeting tau aggregates, or components thereof. In one specific embodiment, the invention include the novel use of polyserine repeat sequences, and/or serine-rich sequences, which may be coupled with a heterologous peptide, to target tau aggregates, or components thereof, and thereby localize the heterologous peptide to the tau aggregate.